BIRC5 (Baculoviral IAP repeat containing 5)

The exploratory predictive model based on post-treatment indicators demonstrated good discrimination for recurrence (AUC = 0.812, 95% CI: 0.747-0.878). In conclusion, as a postoperative adjuvant, Anti-HPV gel demonstrated superior clinical and biomarker outcomes compared to Interferon α-2b gel, with a favorable safety profile and lower short-term recurrence risk, suggesting its promising clinical value pending prospective confirmation.

Molecular docking indicated that the designed compounds interact with key residues of Survivin through covalent and non-covalent interactions. The selected compound may suppress tumor proliferation via Survivin inhibition, constituting a potential lead for cancer therapy.

The siMCL-1/siSur@MPPM nanocarriers demonstrated a significant anti-tumor effect in an in vivo mice model through the silencing of target genes and the induction of apoptosis. These results indicate that the biodegradable siMCL-1/siSur@MPPM nanocarrier provides a significant combination of targeted delivery, biodegradability, effective gene silencing, and reduced off-target effects, suggesting its potential as a promising nanomedicine for breast cancer treatment.

This strategy integrates multiple elements and AND logic gates into a single smart nanoamplifier for precise and boost disruption of mitochondrial redox homeostasis in tumor cells. We believe this work will provide a smart and effective paradigm for tumor therapy.

Additionally, our research team has identified a novel molecular subtype of BLCA that exhibits high expression of PD-L1 but may potentially exhibit resistance to ICB therapy. These findings offer valuable insights into comprehensively characterizing the immunosuppressive tumor microenvironment in BLCA and present opportunities for deepened scrutiny of immunotherapy resistance mechanisms and optimization of targeted immunotherapeutic regimens.

The findings of this study demonstrate that the BPL-DE extract significantly induced the p53-mediated intrinsic apoptotic pathway in HeLa cell lines and provides a potential alternative therapeutic agent for cervical cancer treatment by minimizing damage to normal cells.

To this end, clarifying the potential mechanisms and molecular regulation of cancer stem cell dormancy is vital. Here, in this review, we examine recent significant findings regarding tumor stem cell dormancy in both experimental and human disease models, emphasizing the underlying molecular mechanisms, regulatory processes, experimental models, and prospective research directions aimed at advancing this field and enhancing clinical translation.

Early clinical candidates, such as EZN-3042 and ALN-VSP, achieved target engagement and biological activity, while limitations included variable tumour uptake, dose-limiting toxicities, and complex pharmacokinetic behaviour. Translation to clinical practice will depend on optimised delivery platforms, reproducible pharmacokinetic/pharmacodynamic synchronisation, and rigorous evaluation of safety and off-target effects. Overall, current evidence highlights substantial potential for siRNA-drug co-delivery while emphasizing key challenges to overcome in achieving durable clinically meaningful outcomes.

Furthermore, pharmacogenomic analysis revealed that high expression of this axis correlates with sensitivity to chemotherapy agents like Vinblastine, suggesting a potential stratification strategy for patients with immune-excluded tumors...Collectively, this study highlights spatial determinants of immune exclusion and chemotherapy sensitivity- and presents a generalized machine- learning tool for precision immunotherapy stratification. The developed online resource is freely available to facilitate community-wide biomarker discovery.

Silencing of SNHG10 decreases cell survival, proliferation, clonogenicity, EMT tumor growth through the EGFR/AKT/ERK/mTOR axis, and restores the expression of miR-150-5p, which eventually downregulates VEGF-A. SNHG10 downregulation enhanced the gemcitabine sensitivity in gemcitabine-resistant PDAC cells.

These results indicate the differential effect of allelic variants of six SNPs on prostate cancer risk in patients with overweight or obesity. Further studies in larger cohorts should be conducted to confirm these findings.